Objective To investigate the effects of Baihe Dihuang decoction combined with standardized chemotherapy regimen on the sputum negative conversion rate and the levels of serum T lymphocyte subsets in elderly patients with pulmonary tuberculosis. Methods This study was a randomized controlled trial. A total of 106 elderly patients with pulmonary tuberculosis who were treated in the Third Hospital of Yulin from January 2022 to January 2024 were selected and were divided into a control group and a study group by the random number table method. In the control group, 26 males and 27 females, aged (65.83±3.75) years, with a body mass index of (21.26±1.19) kg/m2, received standardized chemotherapy regimen (2HRZE/4HR, H: isoniazid, R: rifampicin, Z: pyrazinamide, E: Ethambutol), oral isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months; after that, oral isoniazid tablets and rifampicin capsules were continued for 4 months. In the study group, 28 males and 25 females, aged (66.19±3.59) years, with a body mass index of (21.23±1.20) kg/m2, were treated with Baihe Dihuang decoction on the basis of the control group, one dose per day, divided into two times before morning and evening meals, and continued to be administered during the treatment of standardized chemotherapy regimen for 6 months. The observation indicators included the sputum negative conversion rate, traditional Chinese medicine (TCM) syndrome score, lung function indices [forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF)], blood gas indices [arterial oxygen pressure (PaO2), arterial carbon dioxide pressure (PaCO2), and oxygenation index (OI)], and changes in levels of serum T lymphocyte subsets (CD3+, CD4+, and CD4+/CD8+), and the occurrence of adverse reactions during treatment was recorded. χ2 test and t test were used for statistical analysis. Results After treatment, the sputum negative conversion rate in the study group was higher than that in the control group [86.79% (46/53) vs. 66.04% (35/53)], with a statistically significant difference (χ2=6.334, P=0.012); the scores of dry cough and fatigue, hot flusher and night sweats, hot hands and heart, and fine and rapid pulse were lower than those in the control group [(0.65±0.16) points vs. (0.78±0.15) points, (0.58±0.13) points vs. (0.66±0.19) points, (0.59±0.17) points vs. (0.71±0.16) points, (0.58±0.18) points vs. (0.69±0.20) points]; the levels of FEV1, FVC, PEF, PaO2, OI, CD3+, CD4+, and CD4+/CD8+ were higher than those in the control group [(1.23±0.26) L vs. (1.02±0.11) L, (2.06±0.28) L vs. (1.87±0.31) L, (1.29±0.22) L/s vs. (1.14±0.20) L/s, (63.28±5.88) mmHg (1 mmHg=0.133 kPa) vs. (60.17±6.24) mmHg, 400.65±30.90 vs. 387.16±29.42, (68.78±6.53) ×109/L vs. (65.01±6.41) ×109/L, (41.59±3.46) ×109/L vs. (38.97±3.51) ×109/L, 1.58±0.22 vs. 1.36±0.19], but the PaCO2 was lower than that in the control group [(45.02±4.47) mmHg vs. (47.79±4.16) mmHg], with statistically significant differences (all P<0.05). The incidence of adverse reactions in the study group was 9.43% (5/53), which was lower than that in the control group [24.53% (13/53)], with a statistically significant difference (χ2=4.283, P=0.038). Conclusion Baihe Dihuang decoction combined with standardized chemotherapy regimen significantly enhances the sputum negative conversion rate and may improve immune function via elevated CD4+ T cell level, offering a potential adjunct therapy for treating elderly patients with pulmonary tuberculosis.